Document:

Exhibit 10.11

    
      

    

    

      AMENDMENT
        TO LICENSE AGREEMENT

      

      

      Amendment
        to License Agreement by and between TheraCour Pharma, Inc., ("Theracour")
        as Licensor, and NanoViricides, Inc., (“Nano”) as Licensee.

      

      
        The
          License Grant in paragraph 2 is amended and restated as follows:

        

        1)
          License
          Grant. Theracour hereby grants to Nano a limited, non-transferable.
          exclusive
          license,
          subject to the provisions of paragraph 2.2 as amended
          below, for the manufacture, use, sale, or offer of sale of the Licensed
          Product( s) in the Territory.

        

        2)
          Paragraph
          2.1 of the said License Agreement is amended to include “Rabies Virus”.

        

        3) Paragraph
          2.2 of the said License Agreement is clarified, superseded, and replaced
          by the following paragraph:

        

        “TheraCour
          retains exclusive rights to develop and synthesize the different TheraCour
          base polymers used for making the various nanoviricides. A TheraCour base
          polymer
          is defined as a polymer that does not have the virus-specific ligand attached
          to
          it as yet and its structure is covered in one or more of the specified
          TheraCour
          patents. TheraCour
          also retains the exclusive rights to research and develop the chemistries
          for
attaching
          the virus-specific ligands to the base polymers. A “ligand” is defined herein as
a
          chemical or biological moiety that is capable of binding to some feature
          of the
          targeted virus
          particle, this enabling targeting to a specific strain, subtype, type or
          class
          of virus, or
          broad
          or multiple classes of viruses. A ligand itself may be a small chemical
          moiety,
          a peptide
          moiety, a fragment of any antibody, an RNA or DNA “aptamer”, or another
chemically
          defined structure. A TheraCour base polymer is also referred to herein
          as a
“nanomicelle”.
          A nanomicelle is thus a component element of the Licensed Products. Further,
          TheraCour agrees to identify, design, and develop ligand(s) necessary for
          the
development
          of the Licensed Products. As to any Licensed Product, TheraCour retains
          the
          initial exclusive right to develop and synthesize the nanomicelles exclusively
          for Nano.
          In
          the event that Theracour is unable to supply the quantities of the
          nanomicelle(s) required
          for manufacture of the Licensed Product(s), then upon notice and after
          any
applicable
          cure periods required under the License agreement, Nano can acquire the
          nanomicelle(s) from other third party providers.

      

       

      
        	
                NanoViricides,
                  Inc.

              	 	
                TheraCour
                  Pharma, Inc.

              
	 	 	 
	/s/
                Eugene Seymour	 	
                /s/
                  Leo Ehrlich

              
	
                By
                  Eugene Seymour, President

              	 	
                By
                  Leo Ehrlich, Vice PresidentExhibit 10.12

    
      

    

    
      	
              

            	
              *Nanotechhnology-Enabled
                Targeted Viricides"

            
	
              A
                Publicly Traded Company, "NNVC"

            
	
              www.nanoviricides.com

            

    

    

    

    Dec
      23,
      2005

    To

    Nguyen
      Tran
      Hien,
      MD, MPH, PhD

    Director

    National
      Institute of Hygiene and Epidemiology (NIHE)

    1
      Yersin
      Street

    Hanoi,
      Viet Nam

    

    Dear
      Dr.
      Hien:

    

    Enclosed
      please find a Memorandum of understanding between NanoViricides, Incorporated,
      USA, and NIHE, Viet Nam, as per our discussions for the purposes of cooperation
      between NanoViricides, Inc., and NIHE for novel nanotechnology-based
prevention
      strategies, therapies and diagnostics strategies for Influenza A subtype
      H5N1,

    

    We
      look
      forward to a fruitful cooperation in many areas.

    

    
      	 	
              Sincerely,

            	 
	 	
              /s/Anil
                R. Diwan

            	 
	 	
              Anil
                R. Diwan, Ph.D.

            	 
	 	
              President
                & Chairman

            	 
	 	
              NanoViricides,
                Inc.

            	 
	 	
              Mobile:
                203-606-9180

            	 
	 	
              email:
                adiwan@nanoviricides.com

            	 
	 	
              or
                adiwan@snet.net

            	 

    

     

    cc:

    Dang
      Duc
      Anh, PhD

    Vice
      Director, NIHE.

    

    

    135
      Wood
      Street, Ste. 205, West Haven, CT 06516, USA.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Memorandum
      of Understanding

    Between

    NIHE,
      Viet Nam and NanoViricides, Inc., USA

    

    NANOVIRICIDES,
      INC. 135 Wood Street, Suite 205, West Haven, CT 06516, and National
      Institute of Hygiene and Epidemiology (NIHE), 1 Yersin Street, Hanoi, Viet
      Nam,
agree
      to
      enter into a scientific research cooperation on the development of
      prevention, diagnostics,
      and therapeutic strategies for Influenza A subtype H5N1, including:

    

      
        	 	
                *

              	
                Research
                  on Novel Nanotechnology-based Vaccines
                  (NanoVaccines),

              

      

      

      
        	 	
                *

              	
                Research
                  on Novel Nanotehnology-based Therapies (NanoViricides),
                  and

              

      

      

      
        	 	
                *

              	
                Research
                  on Novel Nanotechnology-based
                  Diagnostics,

              

      

    

    

    It
      Is
      understood that these development projects will begin as small
      projects. As success
      Is achieved, the projects can be continued for further development.

    

    These
      various strategies are based on the nanotechnology intellectual property and
      products
      of NanoViricides, Inc.

    

    NanoViricides,
      Inc. shall retain all intellectual property rights to
      resulting
      products and
      technologies and shall make full efforts for world-wide protection of such
      intellectual property
      rights.

    

    Certain
      rights for the new nanotechnology products and technologies develop shall
      be
      provided to NIHE for use in Viet Nam.

    

    The
      work
      plan, costs budget, compensation and financial responsibilities of each
party
      to
      the projects shall be determined in the final Agreement.

    

    It
      Is
      understood that both parties will be sharing confidential information and
intellectual
      property of the other party, and will ensure that such information is protected
      to
      its
      fullest and not publicly disclosed except by written consent from the other
      party when
      so
      decided.

    

    Signed:
      December 23, 2005 by both parties at NIHE, Hanoi, Viet Nam

    

    
      	
              /s/
                Nguyen Tran Hien

            	 	
              /s/
                Anil R. Diwan

            	 
	
              Professor
                Nguyen Tran Hien, MD, MPH, PhD

            	 	
              Anil
                R. Diwan, Ph.D.

            	 
	
              Director

            	 	
              President
                & Chairman

            	 
	
              National
                Institute of Hygiene and Epidemiology

            	 	
              Nanoviricides,
                Inc.

            	 
	
              1
                Yersin Street

            	 	
              135
                Wood Street, Ste. 205

            	 
	
              Hanoi,
                Viet Nam

            	 	
              West
                Haven, CT 06516, USA.

            	 

    

    

    Page
      1 of
      1Exhibit 10.13

    
      

    

    

      CONFIDENTIAL
        TREATMENT REQUESTED

      Gencarelli
        Group

      209
        Pennsylvania Avenue, SE

      Washington,
        D.C. 20003

      (202)543-6972

       

      December
        29, 2006

      

      Eugene
        Seymour, MD

      Chief
        Executive Officer

      Nanoviricides,
        Inc.

      135
        Wood
        Street, Suite 205

      West
        Haven, Connecticut 06516

      

      Re:
        Nanoviricides, Inc. Collaboration with U.S. Military and Civilian Research
        Agencies and International Health Agencies, 2006-2007

      

      Dear
        Dr.
        Seymour:

      

      I
        am
        writing to establish a record of work done in recent months to put in place
        formal collaborative arrangements between Nanoviricides, Inc. and U.S. Federal
        research agencies.

      

      U.S.
        Military—wwwwww xxxx xxxx xxxxxxxxx xxx xxxxxxxx xxxxxxx

      

      In
        June
        of 2006 Nanoviricides, Inc. began discussions with Colonel xxxxx xxxxx, Chief,
        xxxxxxxxxx xxxxxxxxx xxxxx, about possible common interests and goals in
        the
        area of anti-viral treatment research. This meeting led to technical discussions
        in September wherein Colonel xxxxxx xxxxxx xxxxxx, Ph.D., Director, xxxxxxxx
        xx
        xxxxx xxxxxxxxx xxxxx, initiated dialogue with Nanoviricides, Inc. about
        a
        Cooperative Research and Development Agreement (CRADA) designed to test the
        effectiveness of the Nanoviricides, Inc. anti-viral approach against three
        diseases of interest at xxxxx, namely Dengue Fever, West Nile Virus and Japanese
        Equine Encephalitis (JEE). 

      

      As
        of
        December 22, 2006, Nanoviricides, Inc. officials have submitted required
        information for formalization of the CRADA and await sign-off by xxxxx officials
        so that work can begin within 45-60 days. This work will initially test a
        combination of the Nanoviricides, Inc. polymer and targeting antibody fragments
        derived from the specified diseases against the three diseases themselves
        in an
        in vitro setting. When these in vitro tests show adequate effectiveness,
        it is
        xxxxx’s intention to continue testing with this combination in primates where
        Dengue fever will be the primary focus. Nanoviricides, Inc. can reasonably
        expects both of these experimental tracks to move forward during the 2007
        calendar year.

      

      
        
          
            
            

          

          
            
            

            
              

            

          

          
            
            

          

        

      

       

      CONFIDENTIAL
        TREATMENT REQUESTED

       

      Page
        2-Nanoviricides, Inc. Collaboration with U.S. Military and Civilian Research
        Agencies, 2006-2007

      

      United
        States National xxxxxxxxx xxx xxxxxxxxx xxx xxxxxxxxxx xxxxxxx
        xxxxxxxxxx

      

      Nanoviricides,
        Inc. began discussions in September of this year with Dr. xxxxxx xxxxxxxxxxx
        Chief, Influenza, SARS, and Other Viral Respiratory Diseases Section Division
        of Microbiology
        and Infectious Diseases xxxxxxxxxxxxx, and program manager xxxxxxx xxxxxxxxxx
        about participating in xxxxx’s Small business testing and evaluation program
        which provides no-cost testing of novel immunotherapeutic treatment and vaccines
        against diseases considered priorities for the Institute. Nanoviricides,
        Inc.
        and xxxxx are now in the process of finalizing paperwork for bioassay (in
        vitro)
        testing to be done against HIV (AIDS), Influenzas, H5N1, SARS, and Herpes
        over
        the next few months. Assuming adequate effectiveness is shown in the in vitro
        testing, the goal will be to move on to animal studies on the same diseases.
        Actual experimentation will be done by xxxxx contractor xxxx xxxxx with all
        costs (other than production of Nanoviricides, Inc. materials) borne by xxxxx.
        xxxxx has indicated that if there are no unforeseen delays, both bioassay
        and
        animal studies could begin before the end of calendar year 2007.

      

      Also
        in
        2006, Nanoviricides, Inc. has spent time exploring possible collaboration
        opportunities with foreign research institutes under the auspices of the
        xxx
        xxxxxxxx xxxxxx xxxxxxxxxxxx and the xxxxx xxxxxx xxxxxxxxxxxx. The company
        has
        met on numerous occasions with Dr. xxxx xxxxxxxxx xx xxxx, well known for
        his
        efforts to bring novel pharmaceutical solutions to populations in underdeveloped
        countries where “orphan” or “neglected” disease take an inordinate toll on
        indigenous peoples. One of his most important contributions has been arrangement
        of collaborations with the pharmaceutical industry which have significantly
        reduced river blindness sickness in Africa. With Dr. xxxxxxxxx’s encouragement,
        Nanoviricides, Inc. has met with Dr. xxxxxx xxxxxx, Executive Director, Tropical
        Disease Research Institute of the xxx, in Washington, DC and later in Geneva,
        Switzerland to identify target diseases and research institutes in South
        and
        Central America which that may be potential collaborators. This work is expected
        to produce commercial and humanitarian opportunities relating to diseases
        common
        to this region of the world.

      

      I
        hope
        this summary adequately explains the state of play between Nanoviricides,
        Inc.
        and two key government collaborators. Gencarelli Group stands ready to answer
        detailed questions on these projects.

      

      
        	 	
                /s/
                  Dave Gencarelli

              
	 	
                Dave
                  Gencarelli, Gencarelli Group 

              
	 	
                202-256-6191

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]